| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/20/2013 | CN102101888B Novel polypeptide for resisting tumors caused by EB (Epstein-Barr) viruses, and application and preparation method thereof |
| 03/20/2013 | CN101926992B Recombined attenuated live vaccine for preventing and treating I-type infection of herpes simplex virus and preparation method thereof |
| 03/20/2013 | CN101906166B Streptococcus recombination subunit vaccine and preparation method |
| 03/20/2013 | CN101863963B Helicobacter pylori antigen epitope polypeptide and application thereof |
| 03/20/2013 | CN101768565B Bacillus anthracis capable of displaying PAD4 protein on surface of spore and application thereof |
| 03/20/2013 | CN101654664B Fermentation production method and application of high-yield exopolysaccharide strain and amylase thereof |
| 03/20/2013 | CN101619305B Antihuman CD52 monoclonal antibody hybridoma cell line, monoclonal antibody, engineered antibody, carrier, reagent kit and application thereof |
| 03/20/2013 | CN101611057B Antibody molecules for human il-17 |
| 03/20/2013 | CN101583357B Use of MTOR antagonist and angiogenesis inhibitor for preparing medicine for treating cancer |
| 03/20/2013 | CN101522716B High affinity human antibodies to human IL-4 receptor |
| 03/20/2013 | CN101400783B Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| 03/20/2013 | CN101142236B Adam-9调节剂 Adam-9 modifiers |
| 03/20/2013 | CN101111260B Survivin peptide vaccine |
| 03/19/2013 | US8401800 Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity |
| 03/19/2013 | US8401799 Antibody design using anti-lipid antibody crystal structures |
| 03/19/2013 | US8399650 Mycobacterial antigens expressed during latency |
| 03/19/2013 | US8399630 Engineered anti-IL-13 antibodies, compositions, methods and uses |
| 03/19/2013 | US8399628 Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof |
| 03/19/2013 | US8399627 Antibodies to TNFα |
| 03/19/2013 | US8399618 Immunoglobulin insertions, deletions, and substitutions |
| 03/19/2013 | US8399617 Non-functional P2X7 receptor |
| 03/19/2013 | US8399610 HPV vaccine comprising peptides from host cell proteins |
| 03/19/2013 | US8399609 Treating or preventing extracellular matrix build-up |
| 03/19/2013 | US8399202 Peptides for development of diagnostic and therapeutic agents and methods of using same |
| 03/19/2013 | US8399000 Haemophilus influenzae type IV pili |
| 03/19/2013 | US8398999 Chimeric, hybrid and tandem polypeptides of meningococcal NMB1870 |
| 03/19/2013 | US8398998 Therapeutic composition comprising a botulinum neurotoxin |
| 03/19/2013 | US8398997 Polylysine positively charged backbone, oligoarginine branching group, hydroxypropylcellulose viscosity modifying agent; treating wrinkles, hyperhidrosis, neurologic pain, migraine headache, reducing muscle spasms, preventing or reducing acne |
| 03/19/2013 | US8398996 Staphylococcus aureus proteins and nucleic acids |
| 03/19/2013 | US8398995 Method of inducing immune tolerance to type I diabetes |
| 03/19/2013 | US8398994 Lawsonia vaccine and methods of use thereof |
| 03/19/2013 | US8398993 Immunogenic formulation |
| 03/19/2013 | US8398992 Methods and compositions for polytopic vaccination |
| 03/19/2013 | US8398991 Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG |
| 03/19/2013 | US8398990 Glucan-based vaccines |
| 03/19/2013 | US8398989 Human cystathionine β-synthase variants and methods of production thereof |
| 03/19/2013 | US8398988 Adjuvanting meningococcal factor H binding protein |
| 03/19/2013 | US8398987 Use of platelet glycopeptide IIIa epitopes in the treatment of immune thrombocytopenic purpura |
| 03/19/2013 | US8398986 ADP-ribosylating toxin from listeria monocytogenes |
| 03/19/2013 | US8398985 Antigenic polysaccharides and process for their preparation |
| 03/19/2013 | US8398984 Removal promoters and inhibitor for apoptosis cells in vivo |
| 03/19/2013 | US8398983 Haemophilus influenzae type b (Hib) saccharide conjugates; serotypes; vaccine kits |
| 03/19/2013 | US8398982 Compositions and methods for the diagnosis and treatment of tumor |
| 03/19/2013 | US8398981 Therapeutic agents for alzheimer's disease and cancer |
| 03/19/2013 | US8398980 Subtypes of humanized antibody against interleuken-6 receptor |
| 03/19/2013 | US8398979 Polypeptides, antibody variable domains and antagonists |
| 03/19/2013 | US8398978 Antibodies directed against amyloid-beta peptide and methods using same |
| 03/19/2013 | US8398977 Rage fusion proteins |
| 03/19/2013 | US8398976 Antibodies to EGFL7 and methods for their use |
| 03/19/2013 | US8398975 Antibodies directed to αVβ6 and uses thereof |
| 03/19/2013 | US8398974 c-Met antibodies |
| 03/19/2013 | US8398973 Methods and compositions for preventing adhesion |
| 03/19/2013 | US8398972 Methods of treating dementia using a GM-CSF antagonist |
| 03/19/2013 | US8398970 Method of preventing early Lawsonia intracellularis infections |
| 03/19/2013 | US8398969 Compositions and methods for the treatment of viral hepatitis |
| 03/19/2013 | US8398966 IL-1 binding proteins |
| 03/19/2013 | CA2656259C Process for producing poxviruses and poxvirus compositions |
| 03/19/2013 | CA2556227C Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
| 03/19/2013 | CA2536086C Inhibition of dr3 in the treatment of allergic lung inflammation |
| 03/19/2013 | CA2500248C Peptide derivative fusion inhibitors of hiv infection |
| 03/19/2013 | CA2471702C Human monoclonal antibodies against cd30 |
| 03/19/2013 | CA2453260C Vaccine formulation potentiated by the combination of a dna and an antigen |
| 03/19/2013 | CA2440303C Wt1 modified peptide |
| 03/19/2013 | CA2367901C Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 03/19/2013 | CA2354638C Expression of secreted human alpha-fetoprotein in transgenic animals |
| 03/19/2013 | CA2311647C Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 03/19/2013 | CA2195334C Compositions and methods for enhanced tumor cell immunity in vivo |
| 03/19/2013 | CA1341634C Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humanin (virus hiv) leurs applications au diagnostic des infections dues acertains de ces virus et, le cas echeant, a la vaccination contre le sida |
| 03/14/2013 | WO2013036907A1 Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine |
| 03/14/2013 | WO2013036904A2 Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling |
| 03/14/2013 | WO2013036902A1 Submicron particles to decrease transfusion |
| 03/14/2013 | WO2013036872A1 Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
| 03/14/2013 | WO2013036850A2 Modulation of midbody derivatives |
| 03/14/2013 | WO2013036827A2 Fungal-specific metalloproteases and uses thereof |
| 03/14/2013 | WO2013036795A2 Oncolytic herpes simplex virus and therapeutic uses thereof |
| 03/14/2013 | WO2013036791A2 Modified adenoviral vectors and methods of treatment using same |
| 03/14/2013 | WO2013036712A1 Compositions including beta-glucans and methods of use |
| 03/14/2013 | WO2013036596A2 Serpinf2-binding molecules and methods of use |
| 03/14/2013 | WO2013036585A1 Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity |
| 03/14/2013 | WO2013036574A1 Modified forms of pseudomonas exotoxin a |
| 03/14/2013 | WO2013036465A2 A conditional replicating cytomegalovirus as a vaccine for cmv |
| 03/14/2013 | WO2013036303A2 Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
| 03/14/2013 | WO2013036302A1 Induced tolerogenic dendritic cells for generating cd8+ regulatory t cells |
| 03/14/2013 | WO2013036301A1 Induced tolerogenic dendritic cells for inducing regulatory b cells |
| 03/14/2013 | WO2013036300A1 Compositions and methods related to induced tolerogenic dedritic cells externally loaded with mhc class i-restricted epitopes |
| 03/14/2013 | WO2013036298A1 Allergen-specific induced tolerogenic dendritic cells for allegy therapy |
| 03/14/2013 | WO2013036297A1 Therapeutic protein-specific induced tolerogenic dendritic cells and methods of use |
| 03/14/2013 | WO2013036296A1 Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers |
| 03/14/2013 | WO2013036295A1 Antigen-specific induced tolerogenic dendritic cells to reduce antibody responses |
| 03/14/2013 | WO2013036294A1 Antigen-specific induced tolerogenic dendritic cells to reduce cytotoxic t lymphocyte responses |
| 03/14/2013 | WO2013036293A1 Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods |
| 03/14/2013 | WO2013036032A1 A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate |
| 03/14/2013 | WO2013035906A1 Method for preventing and treating salmonella typhimurium infection |
| 03/14/2013 | WO2013035824A1 Cancer stem cell isolation |
| 03/14/2013 | WO2013035345A2 Dengue-virus serotype neutralizing antibodies |
| 03/14/2013 | WO2013035208A1 ANTIBODY AGAINST MUTANT α-ACTININ-4 |
| 03/14/2013 | WO2013035099A1 Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| 03/14/2013 | WO2013034904A1 Anti-cd40 antibodies, uses and methods |
| 03/14/2013 | WO2013034736A1 Use of staphylococcal superantigen- like 3 (ssl3) as an tlr2 inhibitor |
| 03/14/2013 | WO2013034687A1 Avibacterium paragallinarum rtx toxin |